Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced or Metastatic ER+ Breast Cancer 1

Interventions

pembrolizumab 1034Carboplatin 973Paclitaxel 942Gemcitabine 799Cisplatin 759Docetaxel 699Bevacizumab 637Nivolumab 520Pemetrexed 509Cyclophosphamide 476Capecitabine 475Fluorouracil 425Dexamethasone 410Rituximab 392Oxaliplatin 352Injections 349Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 252Ipilimumab 244Doxorubicin 242Lenalidomide 231Fulvestrant 226fludarabine 221durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × LSZ102 × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡